Skip to Main Content

Top of the morning to you. And a fine one, it is, although a bit nippy here on the Pharmalot campus, where a warm sun is shining, the shortest of short people has left for the local schoolhouse, and the official mascots are happily snoozing. As for us, we are keeping toasty by quaffing cups of delicious stimulation. As always, we invite you to join us. Remember, no prescription is required. And now, time to get on with things. Here are a few items of interest to help you along. Hope your day is successful and do keep us in mind when you hear something interesting …

Two Indian states halted sales of the Avastin cancer treatment, which some doctors also use off-label to treat macular degeneration, after the treatment hampered the vision of 15 patients, Reuters reports. Studies have shown Avastin, which is made by Roche, can help with the eye affliction. But the drug maker has repeatedly warned about the risk of contamination, since vials of the cancer treatment must be divided for eye patients.


The New York attorney general reached a deal with Amphastar Pharmaceuticals to extend a $6 price cut on naloxone, which can reverse an opioid or heroin overdose. The drug maker was widely criticized over the past two years by state officials and members of Congress for its pricing. Last summer, Representative Elijah Cummings, a Democrat from Maryland, said state agencies were paying $41 a dose, a 111 percent increase from June 2014.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!